COMPASS Pathways is a mental health care company focusing on accelerating patient access to evidence-based innovation in mental health. Co. is developing psilocybin therapy through late-stage clinical trials for patients with treatment-resistant depression. Co. has developed a high-purity polymorphic crystalline formulation of psilocybin, COMP360. COMP360 is Co.'s psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. Co.'s investigational COMP360 psilocybin therapy comprises administration of its COMP360 with psychological support from trained therapists with specific persibbel and educational qualifications. The CMPS stock yearly return is shown above.
The yearly return on the CMPS stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CMPS annual return calculation with any dividends reinvested as applicable (on ex-dates).
|